Appendix B
Workshop Speakers*, Moderators†, Invited Discussants‡, and Participants
David Agus, Cedars-Sinai Medical Center‡
Naomi Aronson, BlueCross BlueShield Technology Evaluation Center*†
Suresh Arya, National Institutes of Health
Finley Austin, Roche Pharmaceuticals
Rekha Ayalur, Digene Corporation
Chris Beecher, Metabolon
Al Berg, University of Washington*†
Amy Brownawell, Life Sciences Research Office
Johanna Camara, National Institute of Standards and Technology
Jacek Capala, National Cancer Institute
David Carbone, Vanderbilt University‡
Brian Carey, Foley Hoag LLP
B. Melina Cimler, Beckman Coulter, Inc.‡
Adam Clark, National Cancer Institute
Carolyn Compton, National Cancer Institute†
Rob Danziger, PPD Biomarker Discovery Sciences
Hongue Dai, Rosetta Inpharmatics‡
Felice de Jong, Metabolon, Inc.
Nicholas de Klerk, University of Western Australia
Mark Del Vecchio, Digene Corporation
Nathan Dodder, National Institute of Standards and Technology
James Doroshow, National Cancer Institute*
Elizabeth Dupré, American Enterprise Institute
Mark Fendrick, University of Michigan‡
Helen Francis-Lang, Affymetrix
Richard Frank, GE Healthcare‡
Stephen Friend, Merck and Co., Inc.†
Felix Frueh, Food and Drug Administration
Marios Gavrielides, Food and Drug Administration
Robert Gillies, University of Arizona‡
Todd Golub, The Broad Institute of Harvard and MIT*
Mark Gorman, National Coalition for Cancer Survivorship
Steven Gutman, Food and Drug Administration
Susanne Haga, Duke University
Mark A. Heller, Wilmer Cutler Pickering Hale and Dorr*
Judith Hellerstein, University of Maryland‡
Ronald Hendrickson, Merck and Co., Inc.‡
Stuart Hogarth, University of Cambridge
Janet Jamison, National Cancer Institute
Gail Javitt, Genetics and Public Policy Center
Carolyn Jones, Advanced Medical Technology Association (AdvaMed)
Sharon Kim, Precision Therapeutics
Hon-Sum Ko, Food and Drug Administration
Walter Koch, Roche Molecular Systems‡
Paul Lambotte, Quidel Corporation
Michael Leuther, Roche Diagnostics
Rob Lipshutz, Affymetrix*
Donna Marino, HistoRx
Jay Markowitz, T. Rowe Price
Cheryl Marks, National Cancer Institute
Hela Masmoudi, George Washington University
Marilyn Mason, U.S. Department of Veterans Affairs
Lynne McBride, BD Biosciences
Robert McDonough, Aetna U.S. Healthcare†
William T. McGivney, National Comprehensive Cancer Network*†
Steve McPhail, Expression Analysis
Amita Mehratra, National Institutes of Health
Christian Meisel, F. Hoffman-La Roche AG
David Meltzer, University of Chicago*
Zhibao Mi, Precision Therapeutics
Hal Moses, Vanderbilt University†
Juli Murphy, Genetics and Public Policy Center
Ruth Neta, Department of Energy
Nancy Nelson, Journal of the National Cancer Institute
David R. Parkinson, Biogen Idec, Inc.†
Scott Patterson, Amgen, Inc.‡
Edith Perez, Mayo Clinic ‡
Omar Perez, Stanford University
Bruce Peterson, PPD Development
Michael E. Phelps, University of California, Los Angeles*
Kathryn Phillips, University of California, San Francisco ‡
William Pignato, W. J. Pignato & Associates
Indra Poola, MD, Howard University‡
M.Suzanne Pursley-Crotteau, National Cancer Institute
John Quackenbush, Harvard School of Public Health*
G.Gregory Raab, Raab & Associates, Inc.
Scott Ramsey, Fred Hutchinson Cancer Research Center†
David Ransohoff, University of North Carolina*†
Eddie Reed, Centers for Disease Control and Prevention
Laura Reid, Expression Analysis‡
Henry Rodriguez, National Cancer Institute
Jim Rollins, Centers for Medicare & Medicaid Services*
Charles L. Sawyers, University of California, Los Angeles*
Richard Schilsky, University of Chicago‡
Jeff Schomisch, Guide to Good Clinical Practice
Howard Schulman, PPD Biomarker Services*†
Katie Schutta, American Society for Clinical Oncology
Yvette Seger, The Center for Accelerating Medical Solutions
Richard M.Simon, National Cancer Institute*†
Dee Simons, Roche Diagnostics
Dominick Sinicropi, Genomic Health, Inc.
Margaret Spitz, MD Anderson Cancer Center‡
Juli Staiano, Foundation for the National Institutes of Health
Andrew Stevens, UK National Institute for Health and Clinical Excellence*
Zoltan Szallasi, Harvard Medical School‡
Brian Taylor, Expression Pathology, Inc.
Samantha Truex, Genzyme Corporation
Gayle Vaday, Congressionally Directed Medical Research Programs
John A. Wagner, Merck Research Laboratories*†
Judith Wagner, Institute of Medicine‡
Paul Waring, Genentech*
Barbara Weber, GlaxoSmithKline‡
Scott Weidman, National Research Council
Jean-Pierre Wery, Eli Lilly and Co.‡
Janet Woodcock, Food and Drug Administration*†
Timothy Yeatman, H. Lee Moffit Cancer Center & Research Institute
